Pulmonary route of administration has proved to be an effective way of systematically delivering biopharmaceuticals and drugs to treat pulmonary and non-pulmonary diseases. It offers several advantages such as high permeability rate, low enzymatic activity, high blood circulation, quick onset of action, non-invasive delivery of drugs, and large surface area for absorption.
Constant Technological Improvements to Stimulate Preference for Dry Powder Inhalers
Some of the common products used in pulmonary drug delivery are dry powder inhalers, metered dose inhalers, accessories, and nebulizers. Metered dose inhalers (MDI) represented the leading share in 2016. A large number of prominent players are involved in extensive R&D activities to launch novel MDIs, which in turn is supplementing the growth of the segment. High acceptance rate of these devices in emerging economies of Latin America and Asia Pacific likely to keep their sales high through 2025.
The dry powder inhaler (DPI) segment is anticipated to register noteworthy growth in coming years. Rapid technological advancements are expected to play a vital role in the growth of the segment. These inhalers offer merits such as short administration and preparation time and cost-effectiveness.
Demand for nebulizers is estimated to witness steady rise over forthcoming years. Nebulizers have a strong adoption rate in homecare and hospitals owing to their advantages such as large dosage administration, greater comfort, and conducive reimbursement scenario. Approval of novel devices will further augment the growth of the segment. For instance, in December 2017, FDA approved Lonhala Magnair (glycopyrrolate) inhalation solution, a nebulized long-acting muscarinic antagonist (LAMA) for the treatment of airflow obstruction in patients with COPD.
Market Insights
Market Insights
According to a report by Grand View Research Inc., the global pulmonary drug delivery market is projected to expand at a CAGR of 4.7% between 2017 and 2025 (forecast period). Rising incidence of chronic respiratory diseases is likely to escalate the growth of the market. As per the findings of “The Global Asthma Report 2014” issued by the Global Asthma Network (GAN), asthma affects close to 334 million people across the world. Besides this, limitations of conventional treatments, including low efficacy and late onset of action, are encouraging the development of advanced pulmonary drug delivery systems, which in turn is poised to propel the market.
North America dominated the market in 2017. The growth of the market can be attributed to the presence of advanced healthcare infrastructure and growing population of geriatrics. Some of the key players in the global arena are GlaxoSmithKline plc, Boehringer Ingelheim GmbH, 3M Healthcare, AstraZeneca, and Novartis AG.
In-Depth Research Report On Pulmonary Drug Delivery Devices/Systems Market:
https://www.grandviewresearch.com/industry-analysis/pulmonary-drug-delivery-systems-market
No comments:
Post a Comment